Laboratorios Rovi : Q4 2023 preview. Target valuation revised upwards on higher Risvan certainty
>Soft sales momentum due to a hard comp. Underlying prescription pharma evolution remains solid - The company is due to publish its Q4 2023 results on 27 February before the market opens. We expect a deterioration in the sequential momentum of sales, declining 9% y-o-y to € 221m (vs +10% in Q3, +2% in Q2 and -2% in Q1), which is explained by a strong comparison basis in Q4 2022 (when its CMO unit reached its quarterly high watermark of € 136m), while the ongoing launc...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.